# Arimidex With or Without Faslodex In Postmenopausal Women With HR Positive Breast Cancer

> **NCT00570323** · PHASE2 · COMPLETED · sponsor: **Mothaffar Rimawi** · enrollment: 72 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Arimidex
- **DRUG:** Faslodex

## Key facts

- **NCT ID:** NCT00570323
- **Lead sponsor:** Mothaffar Rimawi
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-12
- **Primary completion:** 2016-10
- **Final completion:** 2018-12-05
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2020-07-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00570323

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00570323, "Arimidex With or Without Faslodex In Postmenopausal Women With HR Positive Breast Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00570323. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*